Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India

Jain, Romesh; Mallya, M V; Amoncar, Sangeeta; Palyekar, Sachin; Adsul, Harshad Popat; Kumar, Rakesh; Chawla, S.K.

doi:10.1016/j.tracli.2021.07.004

Cited by 8 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, blood operators needed to identify and develop approaches to qualify blood donors for CCP donations when no gold standard COVID-19 serological tests existed [ 46 , 47 ]. This included creating deferral policies for CCP donors who were convalescing after SARS-CoV-2 infection [ 65 ]. Blood operators developed early expertise in characterizing SARS-CoV-2 serological assays [ 10 , 51 , 55 ].…”

Section: Lessons Learnedmentioning

confidence: 99%

Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic

Drews

O’Brien

2022

Viruses

View full text Add to dashboard Cite

Humans interact with virus-infected animal hosts, travel globally, and maintain social networks that allow for novel viruses to emerge and develop pandemic potential. There are key lessons-learned from the coronavirus diseases 2019 (COVID-19) pandemic that blood operators can apply to the next pandemic. Warning signals to the COVID-19 pandemic included outbreaks of Severe acute respiratory syndrome-related coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome-related coronavirus (MERS-CoV) in the prior two decades. It will be critical to quickly determine whether there is a risk of blood-borne transmission of a new pandemic virus. Prior to the next pandemic blood operators should be prepared for changes in activities, policies, and procedures at all levels of the organization. Blood operators can utilize “Plan-Do-Study-Act” cycles spanning from: vigilance for emerging viruses, surveillance activities and studies, operational continuity, donor engagement and trust, and laboratory testing if required. Occupational health and donor safety issues will be key areas of focus even if the next pandemic virus is not transfusion transmitted. Blood operators may also be requested to engage in new activities such as the development of therapeutics or supporting public health surveillance activities. Activities such as scenario development, tabletop exercises, and drills will allow blood operators to prepare for the unknowns of the next pandemic.

show abstract

Section: Lessons Learnedmentioning

confidence: 99%

Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic

Drews

O’Brien

2022

Viruses

View full text Add to dashboard Cite

show abstract

“…При этом стоит отметить, что для нейтрализации не менее 90% рецептор-связывающих доменов S-белка необходимо присутствие в крови количества антител в среднем 327,2±6,5 BAU/мл. Тем не менее единичные случаи свидетельствуют о том, что наличие высокого уровня антител не всегда определяет нейтрализующую активность и наоборот, что требует мониторинга данных показателей среди доноров плазмы [8].…”

Section: среднееunclassified

Humoral immunity in reconvalescents and persons vaccinated against COVID-19: a comparative assessment of the main indices of the humoral immune response

Каримов

Korneev

Borisov

et al. 2022

Russian Journal of Immunology

View full text Add to dashboard Cite

Specific humoral immunity to SARS-CoV-2 develops due to the formation of neutralizing IgG, which can primarily block the receptor-binding domain of the viral S-protein. The duration of post-infection immunity, as well as avidity of circulating antibodies, play an important role in this process. The aim of this work was to evaluate the amounts of antibodies to SARS-CoV 2 S-protein, their avidity and neutralizing activity in the studied samples of the post-COVID patients versus vaccinated seropositive individuals. Materials and methods. A sample of 113 individuals was studied, which consisted of three experimental groups, i.e.: recovered, vaccinated, as well as recovered and vaccinated persons. Blood serum specimens of the individuals were studied for specific IgG to SARS-CoV-2, along with determination of their quantities (BAU/mL) using Vector-Best kits (Novosibirsk, Russia). The avidity index was determined using a kit manufactured by MedipalTech (Dubna, Russia). Neutralizing ability of the antibodies was assayed by means of ELISA with diagnostic kits from MedipalTech (Dubna, Russia), which resulted into percentage of neutralized S-proteins to RBD. Results. The average levels of IgG did not show significant differences between reconvalescents and vaccinated persons. However, both indicators were significantly lower than those from the groups who recovered from the disease and were vaccinated. A cyclic change in the numbers of antibodies was observed, along with most intensive drop in the level of immunoglobulins over first four months after the illness or vaccination. Despite initially similar levels of immune parameters in both groups, the decline of this index in vaccinated group was significantly higher than in the recovered group, thus allowing us to conclude that the amounts of specific antibodies in this group was shown to be decreased to zero levels as soon as by the 10th month. IgG index among the recovered and vaccinated groups remained unchanged for the entire anamnestic period. Avidity index of the antibodies in vaccinated individuals was higher than in recovered individuals. Meanwhile, this index in both groups was characterized by stable increase over the observation period of 7 to 11 months. The highest levels of antibodies and their avidity were noted in the group of recovered and vaccinated individuals, due to the most complete activation of the immune system. A straight-line trend was revealed for the decreasing index of neutralizing activity during the considered time period. The overall pattern of thee results shows that the neutralizing activity of antibodies is largely determined by the amounts of SARS-CoV-2-specific immunoglobulins. Thus, the time dynamics of antibodies to SARS-CoV-2 in various groups of examined individuals was revealed. Direct correlation was established between the neutralizing activity and amounts of immunoglobulins, as well as the role of vaccination for increased avidity of antibodies.

show abstract

“… Abs-based therapy may be advantageous for B-CD patients. Oren Gordon et al 154 Pharmacokinetics of HT anti-SARS-CoV-2 human CP in HR children (ORA) Prospectively enrollment May 2020 and April 2021 Johns Hopkins Children’s Center 14 HR children Registered prospectively for HT COVID-19 CP (>1:320 anti-spike IgG; Euroimmun) HT COVID-19 CP was administered to 14 HR children (median age, 7.5 years), 9 of whom received it within 5 days (range, 2–7 days) after the beginning of symptoms and 5 of whom received it within 4 days (range, 3–5 days) of SARS-CoV-2 exposure. Regardless of weight or age, CP transfused to HR children seems to be safe and has the observed Abs kinetics.…”

Section: Introductionmentioning

confidence: 99%

“… Regardless of weight or age, CP transfused to HR children seems to be safe and has the observed Abs kinetics. R. Jain et al From India 154 Analysis of SARS-CoV-2 seroprevalence among potential CP donors and their deferral patterns: Results from a tertiary care institution in western India (ORA) Prospective study August 2020 to December 2020 -The department of blood banks at the tertiary care referral center, Goa medical college in western India. 400 prospective CP donors IgG SARS-CoV-2 Abs seroprevalence was 87% in prospective CP donors.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula¹,

Tuji²,

Gudeta³

et al. 2023

JBM

View full text Add to dashboard Cite

Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

show abstract

Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India

Cited by 8 publications

References 19 publications

Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic

Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic

Humoral immunity in reconvalescents and persons vaccinated against COVID-19: a comparative assessment of the main indices of the humoral immune response

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Contact Info

Product

Resources

About